Revolution Medicines Inc (RVMD) is a Healthcare · Biotechnology company listed on NASDAQ. Price $190.95 (-3.04%), Market cap $31.96B, 52-week low–high $34.70 ~ $153.73.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON) inhibitors that binds RAS variants to be used as monotherapy in combination with other RAS(ON) inhibitors and/or in combination with RAS companion inhibitors or other therapeutic agents, and RAS companion inhibitors to suppress cooperating targets and pathways that sustain RAS-addicted cancers. Its RAS(ON) inhibitors include daraxonrasib (RMC-6236), elironrasib G12C (RMC-6291) which is in early clinical development for the treatment of solid tumors, and zoldonrasib G12D (RMC-9805), which are in
Financial statements, price targets, institutional (13F) holdings and related news for Revolution Medicines Inc are updated in real time on BlackAll Trade.
Revolution Medicines Inc trades at $190.95 (-3.04%). Real-time quotes and charts are available on BlackAll Trade.
Revolution Medicines Inc has a market cap of about $31.96B.
Revolution Medicines, Inc., a clinical-stage precision oncology company, develops novel targeted therapies for RAS-addicted cancers. The company's research and development pipeline consist of RAS(ON)